Korea Investment Partners

Raywatt is a startup focused on developing innovative medical devices for cardiovascular interventions. The company specializes in a health technology platform that utilizes laser-based imaging technology to enhance the diagnosis and treatment of cardiovascular diseases. Raywatt's offerings include optical coherence tomography (OCT)-based machine learning for fractional flow reserve (FFR) prediction, as well as catheter-based high-speed OCT imaging. These advanced imaging technologies provide healthcare professionals with high-speed and high-resolution tools to improve patient outcomes in the field of cardiology.

Healing Paper leverages information technology to enhance accessibility to medical services, reduce costs, and facilitate balanced communication between healthcare professionals and non-experts.

Gangnam Unni is in the field of beauty medical services, helping users choose a treatment and a plastic surgery hospital. The difficulty of navigating the process of seeking medical treatment and choosing a hospital continues to persist. Kangnam Unni recognizes the need for change and firmly believes that a combination of transparent medical information and an IT platform can foster a consumer-oriented medical service market. Their ultimate goal is to challenge negative perceptions surrounding plastic surgery and spearhead a significant transformation in the beauty and medical service industries. The Gangnam Unni team is dedicated to innovation, fueled by an unwavering desire to provide exceptional beauty and medical services. With the aim of assisting individuals in selecting a suitable hospital, they have amassed an impressive database of one million user reviews. Additionally, their efforts to promote transparency in medical information have garnered the support of 3,000 subscribers through Gangnam Sister. Furthermore, their mobile application has facilitated hospital consultations for a staggering 3.8 million individuals, resulting in 1.6 million successful cases. As the team continuously clarifies its mission and forges ahead with determination, its collective strength and resolve only grow stronger. Kangnam Unni remains committed to revolutionizing the healthcare industry, ensuring that individuals receive the highest quality of care and a positive experience throughout their medical journeys.

Selta Square is a company specializing in AI-driven drug monitoring solutions. It employs artificial intelligence technology to offer comprehensive drug monitoring services, allowing pharmacovigilance experts to minimize repetitive tasks and focus on critical evaluations.

MyHerb Healthcare proivdes a specialized analysis for nutritional supplements.

Raywatt is a startup focused on developing innovative medical devices for cardiovascular interventions. The company specializes in a health technology platform that utilizes laser-based imaging technology to enhance the diagnosis and treatment of cardiovascular diseases. Raywatt's offerings include optical coherence tomography (OCT)-based machine learning for fractional flow reserve (FFR) prediction, as well as catheter-based high-speed OCT imaging. These advanced imaging technologies provide healthcare professionals with high-speed and high-resolution tools to improve patient outcomes in the field of cardiology.

Pin Therapeutics is a biotechnology company developing therapeutic products that target disease-causing proteins for immune diseases, cancer, and aging-related conditions. It employs protein degradation systems to break down these proteins.

ALDAVER provides incredibly realistic personalized surgical training models using innovative biopolymer materials that closely resemble human tissues and 3D printing technology.

Brave Company is a wellness enterprise that develops and markets consumer health brands, focusing on convenient, nutritious products like chicken breast and diet foods. Their mission is to transform daily health habits by integrating their offerings into everyday routines, such as exercise, meals, and social activities. They achieve this by supporting and collaborating with creators through a platform that provides brand incubation, marketing support, personalized recommendations, performance analytics, and offline fitness facilities.

MicrobiotiX develops bacteriophage and microbiome-based therapeutics to combat multidrug-resistant infections and autoimmune diseases, and pursues therapeutic diagnostic technologies to enable microbiome-focused treatments. The company’s platform supports safe gastrointestinal microbiota transplant in a medical setting, formulates fecal microbiota transplant capsules for oral administration, and conducts research and development of bacteriophages, with the aim of delivering convenient, economical therapies that reduce infection risk. Through these approaches, MicrobiotiX seeks to advance microbiome and phage therapies for difficult-to-treat conditions, integrating diagnostics with therapeutics to streamline patient care.

Bio Design Lab is a biotechnology company focused on the development of biopharmaceutical products, specifically in the areas of gene, cell, and immunotherapies. The company employs systems-level genetic and genomic design strategies to create potent drugs aimed at addressing a range of diseases. By utilizing advanced methodologies, Bio Design Lab aims to enhance the efficiency of drug development processes for healthcare organizations, ultimately contributing to the creation of effective therapeutic solutions.

Allround Doctors is a digital healthcare startup that develops digital medical devices for cancer patients.

Thorough Future specializes in integrating advanced technology into medical care. It focuses on enhancing diagnostic services' accuracy and efficiency for clinical medicine and providing personalized treatment recommendations, particularly for cancer patients.

Syntekabio, Inc. is a bioinformatics company based in Daejeon, South Korea, founded in 2009. The firm specializes in genome analysis and the integration of bio data, utilizing advanced algorithms to create personal genome maps that facilitate disease prevention and the development of customized medications. Syntekabio also offers a technology for collecting and integrating decrypted whole genome data, which is instrumental in analyzing diseases, including rare conditions. Their MAHA supercomputer significantly reduces data-processing costs and enhances genome-based diagnostics. The company focuses on gene-related research and technology development, leveraging a genome big data platform and artificial intelligence for drug development and genetic analysis.

PulseSight Therapeutics is an ophthalmology-focused biotechnology company developing treatments for severe retinal diseases. It advances non-viral gene therapies delivered through minimally invasive methods to address blindness associated with retinal conditions. In addition, the company develops therapeutic proteins aimed at treating both short- and long-term retinal disorders, including chronic non-infectious uveitis, degenerative diseases, retinal vascular diseases, and macular edema. These approaches seek to improve ocular bioavailability and tolerability while supporting adherence to treatment. By focusing on therapies that preserve and improve vision, PulseSight aims to provide physicians and ophthalmologists with options that address unmet clinical needs and improve patient quality of life.

DYNE Medical Group is a medical equipment manufacturer specializing in endoscopy devices and artificial intelligence solutions for urological surgery. The company focuses on developing innovative manufacturing technologies that incorporate reusable flexible endoscopes, utilizing a unique optimization design and ultra-precision processing. This advanced approach aims to enhance the effectiveness of endoscopic procedures, facilitating minimally invasive treatments for patients. Additionally, DYNE Medical Group is committed to providing AI-based cancer diagnostics, further supporting healthcare professionals in delivering improved patient care.

CareMedi is a healthcare company specializing in the development of innovative medical devices, particularly a wearable drug pump designed to enhance the quality of life for individuals with diabetes. The company's platform offers a range of healthcare products, including medical equipment, nebulizers, aspirators, and massagers. By enabling consumers to conveniently order these products from home, CareMedi aims to improve overall lifestyle and health outcomes for its users.

Brexogen is a biotechnology company focused on cell therapy research and development. It specializes in creating optimized parental cells for exosome production, aiming to treat incurable diseases through stem cell exosomes.

BiomATZ is a biotechnology company focused on developing microbiome therapeutics through its proprietary platform. This innovative platform isolates and analyzes the complex interactions within gut microbiota to create cooperative microbial consortia. By leveraging a bank of intestinal microorganism strains, BiomATZ facilitates the identification of optimal functional strain combinations, which can enhance the efficacy of live biotherapeutic products. The company is dedicated to advancing personalized medicine and improving gut health solutions, with potential applications in pharmaceuticals, nutraceuticals, and functional foods. Through its research and development efforts, BiomATZ aims to contribute significantly to the field of microbiome science and its therapeutic applications.

Thorough Future specializes in integrating advanced technology into medical care. It focuses on enhancing diagnostic services' accuracy and efficiency for clinical medicine and providing personalized treatment recommendations, particularly for cancer patients.

Vedanta Biosciences is a clinical-stage microbiome company focused on developing therapies for immune-mediated and infectious diseases using live bacteria derived from the human microbiome. The company designs orally delivered defined bacterial consortia, leveraging libraries of microbiome-derived strains, proprietary datasets from human interventional studies, and tools for selecting potent strains. Its platform encompasses consortium design and CGMP manufacturing of bacterially defined products, enabling physicians to access live bacteria drugs for autoimmune and inflammatory conditions. Headquartered in Cambridge, Massachusetts, Vedanta Biosciences aims to create a new category of oral therapies arising from defined bacterial communities grown from clonal cell banks.

Cashwalk is an app that incentivizes users to walk more by offering financial rewards. It provides a pedometer function and aims to promote healthier lifestyles, particularly for individuals managing chronic diseases like hypertension, hyperlipidemia, and diabetes.

S-Alpha Therapeutics Inc. is a digital therapeutics company based in Seoul, South Korea, established in 2019. It specializes in researching and developing health applications and platform technologies that leverage digital devices for the treatment of various diseases. The company’s product pipeline includes SAT-001, an application focused on ophthalmology for eye disease treatment; SAT-002, which addresses neurological conditions; SAT-003, designed for oncology to support cancer patients in their recovery; and SAT-008, aimed at public crises to address social issues. In addition to its health applications, S-Alpha Therapeutics also develops therapeutic devices, striving to provide innovative solutions for unmet medical needs across multiple therapeutic areas, including ophthalmology, neuropsychiatry, and cancer.

S&E Bio is a biopharmaceutical company specializing in the development of cell therapies aimed at addressing neurological disorders. The company focuses on creating safe and effective treatments using stem cell-derived extracellular vesicles, particularly mesenchymal stem cell-derived therapeutics. S&E Bio targets a range of conditions, including acute stroke, moyamoya disease, chronic stroke, dementia, and cognitive disorders. Through its innovative approach to stem cell therapy, the company seeks to provide advanced treatment options for patients suffering from these incurable diseases, enhancing their quality of life and treatment outcomes.

Rgenta Therapeutics, Inc. is a biotechnology company focused on developing RNA-targeting medicines aimed at treating oncology and neurological disorders. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes a proprietary platform that analyzes extensive genomic data to identify targetable RNA processing events. This innovative approach enables the design of small-molecule glues that modulate interactions among the spliceosome, regulatory proteins, and RNAs. Rgenta's unique methodology aims to unlock the therapeutic potential of previously undruggable targets, ultimately advancing drug development for human diseases.

S&E Bio is a biopharmaceutical company specializing in the development of cell therapies aimed at addressing neurological disorders. The company focuses on creating safe and effective treatments using stem cell-derived extracellular vesicles, particularly mesenchymal stem cell-derived therapeutics. S&E Bio targets a range of conditions, including acute stroke, moyamoya disease, chronic stroke, dementia, and cognitive disorders. Through its innovative approach to stem cell therapy, the company seeks to provide advanced treatment options for patients suffering from these incurable diseases, enhancing their quality of life and treatment outcomes.

Agilis Robotics is a developer of flexible robotic instruments specifically designed for endoluminal surgery. The company's technology enhances the dexterity and precision available to clinicians during surgical procedures, particularly in the examination and operation of various organs, including the digestive tract, lower abdomen, large bowel, and bladder. By integrating seamlessly with existing clinical workflows, Agilis Robotics aims to improve surgical outcomes and support surgeons in their efforts to provide effective patient care.

Innogen Pharmaceutical Technology is an international biopharmaceutical company specializing in the development and manufacturing of innovative drugs. The company utilizes advanced genetic engineering and recombinant protein biopharmaceutical processes to create new therapies. Its primary focus is on addressing the treatment needs of patients suffering from diabetic metabolic diseases and significant central nervous system disorders. Through its research and development efforts, Innogen aims to deliver effective solutions that enhance patient care and improve health outcomes.

LumanLab develops digital therapeutics designed to address developmental delays. The company also offers an AI-based digital healthcare companion that identifies and monitors developmental concerns in children, featuring behavior analysis tools and video-based assessment to help parents, teachers, and healthcare professionals observe patterns and support timely intervention.

Yibai Technology is a specialist in healthcare-based software-as-a-service.

Founded in 2016, Geneos Therapeutics specializes in developing personalized cancer immunotherapies targeting neoantigens. Its proprietary platform enables the creation of tailored treatments based on individual patients' tumor mutations.

Founded in 2017, Dr.Diary is a South Korean company specializing in diabetes management solutions. Its flagship application helps users monitor blood sugar levels, track exercise routines and food intake, receive personalized health insights, and communicate with healthcare professionals.

Pin Therapeutics is a biotechnology company developing therapeutic products that target disease-causing proteins for immune diseases, cancer, and aging-related conditions. It employs protein degradation systems to break down these proteins.

Yeoshin is a skin treatment information platform.

One Curegen develops diagnostic anti-cancer drugs.

Limbix is a company dedicated to developing prescription digital therapeutics for adolescent mental health. Their flagship product, SparkRx, is an evidence-based, clinically validated tool designed to treat depression and anxiety in teenagers. Limbix combines clinical expertise with technological innovation to deliver effective mental health treatments.

PDC*line Pharma is a French-Belgium clinical-stage biotech company developing active immunotherapies for cancer using its proprietary Plasmacytoid Dendritic Cell line, PDC*line. These therapies aim to stimulate potent and scalable antitumor immune responses.

Otus is a healthcare institute that specializes in advanced eyecare system.

Haoxinqing is an online medical service platform that specializes in mental psychology and chronic disease management. The company offers remote diagnosis and treatment services, allowing patients to access medical care conveniently from their homes. By focusing on these areas, Haoxinqing aims to enhance patient experience and improve health outcomes, making it easier for individuals to manage their mental health and chronic conditions effectively.

GenEdit Inc., established in 2016 and headquartered in Berkeley, California, specializes in developing innovative genome editing tools. The company's core technology is CRISPR/Cas9, which enables precise therapeutic gene editing. GenEdit has further advanced this field by creating the NanoGalaxy™ platform, a proprietary non-viral delivery system that efficiently transports CRISPR/Cas9 to target tissues, overcoming previous delivery challenges. This platform systematically screens a library of nanoparticles to ensure safer and more effective delivery, making therapeutic gene editing easier, faster, and more accurate than traditional methods. GenEdit's ultimate goal is to facilitate the cure of previously incurable genetic diseases by providing physicians with powerful tools for gene therapy.

Immunobiome is a biotechnology company focused on developing microbiome-based therapeutics aimed at treating challenging diseases, including cancer, autoimmune disorders, allergies, and neurological conditions. By leveraging advanced immunology, bioinformatics, and fundamental microbiome research, the company seeks to create innovative solutions that address conditions often deemed incurable. Its platform specializes in targeted treatments that can help manage intractable immune-related diseases and improve patient outcomes in various health challenges, including organ transplant rejections and inflammation-related issues.

Tcino Bioscience develops molecule anti-cancer drugs for cancer patients.

Hala is a nutrition brand.

Eyevensys S.A.S. is a Paris-based company that specializes in non-viral gene therapy for ophthalmology. Founded in 2008, it focuses on developing innovative solutions to improve drug delivery methods for ocular diseases. The company utilizes its proprietary Electro-Transfection (ET) technology to administer plasmids to the ciliary muscle, allowing for the sustained release of therapeutic proteins directly into the vitreous, addressing conditions such as uveitis, age-related macular degeneration, and various retinopathies, including central retinal vein occlusion and diabetic retinopathy. Eyevensys aims to overcome the limitations of current treatment options, which often involve invasive procedures like intravitreal injections and surgeries. By enhancing compliance, ocular bioavailability, and tolerability, Eyevensys seeks to create a robust product pipeline that delivers improved clinical outcomes while minimizing the need for frequent and invasive interventions.

S-Alpha Therapeutics Inc. is a digital therapeutics company based in Seoul, South Korea, established in 2019. It specializes in researching and developing health applications and platform technologies that leverage digital devices for the treatment of various diseases. The company’s product pipeline includes SAT-001, an application focused on ophthalmology for eye disease treatment; SAT-002, which addresses neurological conditions; SAT-003, designed for oncology to support cancer patients in their recovery; and SAT-008, aimed at public crises to address social issues. In addition to its health applications, S-Alpha Therapeutics also develops therapeutic devices, striving to provide innovative solutions for unmet medical needs across multiple therapeutic areas, including ophthalmology, neuropsychiatry, and cancer.

Maxvax Health is a biotechnology company focused on the development and commercialization of innovative vaccines. The company specializes in vaccine technology targeting viral diseases, including rotavirus, shingles, and herpes. By advancing these vaccines, Maxvax Health aims to enhance treatment options for healthcare professionals and improve patient outcomes. Through its efforts in vaccine development, the company seeks to address significant health challenges posed by viral infections.

Tcino Bioscience develops molecule anti-cancer drugs for cancer patients.

Sky Labs is a technology company focused on developing innovative wearable devices for health monitoring, particularly a cuffless ring-type blood pressure monitor and a device known as the Cardio Tracker (CART). The CART is designed for continuous monitoring of atrial fibrillation, a common and often undiagnosed heart condition affecting many individuals over 40. This device can be worn comfortably on any finger and is both waterproof and dustproof, allowing users to wear it throughout their daily activities without interruption. It operates without user intervention, automatically detecting and recording atrial fibrillation, which users can track via a smartphone application. The device aims not only to assist individuals in managing their heart health but also to provide valuable data to healthcare professionals for accurate diagnosis. Sky Labs is currently conducting clinical trials in collaboration with Seoul National University Hospital to validate the performance of its technology, with an initial focus on the atrial fibrillation patient market in Finland, and an extended target market of millions worldwide. The company is also partnering with Bayer to explore further healthcare innovations.

TSD Life Sciences Co., Ltd., established in 2016 and based in Seoul, South Korea, specializes in the research and development of pharmaceuticals targeting rare and intractable diseases, with a primary focus on cancer. The company offers comprehensive clinical research services, including non-clinical studies, clinical trials, orphan drug designation, and project management, aiming to develop innovative antibody drugs for treating previously incurable conditions.

Epibiotech is a healthcare center that provides hair loss treatment solutions.

Hisense Bio offers treatment for intractable dental diseases. They provide research on original technology for tooth development and dentin regeneration. They developed physiological dentin regeneration technology and periodontal ligament regeneration technology based on basic dental research . They offer treatment of intractable dental diseases such as tooth decay, dental hypersensitivity, tooth decay, dental caries, and periodontal disease.

Innogen Pharmaceutical Technology is an international biopharmaceutical company specializing in the development and manufacturing of innovative drugs. The company utilizes advanced genetic engineering and recombinant protein biopharmaceutical processes to create new therapies. Its primary focus is on addressing the treatment needs of patients suffering from diabetic metabolic diseases and significant central nervous system disorders. Through its research and development efforts, Innogen aims to deliver effective solutions that enhance patient care and improve health outcomes.

Founded in 2016, Geneos Therapeutics specializes in developing personalized cancer immunotherapies targeting neoantigens. Its proprietary platform enables the creation of tailored treatments based on individual patients' tumor mutations.

Univercells is a company specializing in high-density, low-cost biomanufacturing solutions aimed at enhancing the production of biologics, including antibodies, proteins, and vaccines. The company leverages innovative engineering and proprietary technologies, such as single-use systems and continuous process intensification, to significantly reduce capital investments by over 75% and the cost of goods by up to 90%. Univercells offers a range of services, including scale-X hydro, scale-X carbo, and NevoLine, which support both research and development and commercial-scale production of biologics. Additionally, the company provides integrated services like equipment confirmation, capacity and facility design, and bioprocess excellence, facilitating the scalability of cell and gene therapy manufacturers from clinical trials to commercial manufacturing. Through its commitment to making biologics more accessible and affordable, Univercells addresses critical global health challenges.

Founded in 2016, Humanscape specializes in blockchain-based health data platforms. It collects comprehensive patient health data, including genotype, clinical, and phenotype information, to facilitate drug discovery and improve treatments for intractable and rare diseases.

Yibai Technology is a specialist in healthcare-based software-as-a-service.

DoctorHere is a smart medical clinic using AI and IT to provide primary care both in-person and virtually

EvidNet is a healthcare IT company focused on providing Real World Evidence (RWE) solutions that leverage hospital data to enhance research and decision-making in the life sciences and healthcare sectors. The company collaborates with over 50 university and tertiary hospitals in Korea to generate Real World Data (RWD) using the OMOP-CDM standard. Its FeederNet® data platform facilitates multi-institutional research and allows for AI-driven federated machine learning, ensuring privacy and security are maintained. EvidNet's platform is designed to support precision and predictive medicine by creating an interoperable, real-time healthcare data network. This network offers tailored statistical analysis to meet the specific needs of hospitals and healthcare providers, enabling easier access to vital health information for both professionals and patients.

Trost Company, established in 2016 and headquartered in Seoul, South Korea, specializes in mental healthcare services. The company offers an array of online counseling options, including an employee assistance program (EAP) designed to support organizations in promoting mental well-being among employees. Utilizing a mobile application named TROST, the company connects users with qualified counselors who provide diagnosis and treatment through virtual consultations. Additionally, Trost offers various self-analysis tests, covering areas such as psychological health, personality assessment, depression, self-esteem, and job-related stress. Through its services, Trost aims to enhance access to mental health resources and foster psychological well-being.

Virogin Biotech Ltd., founded in 2015 and based in Vancouver, Canada, specializes in the development of oncolytic virus therapeutics aimed at treating cancer. The company utilizes its innovative Synerlytic™ technical platform to enhance cancer treatment through novel immunotherapy approaches. Virogin's technology focuses on leveraging immunological principles to stimulate anticancer and antitumor immunity. By harnessing a robust and transient antiviral immune response, the company aims to improve systemic antitumor immunity via synergistic interactions with multiple therapeutic payloads. Virogin is dedicated to advancing its position as a leader in the field of immuno-oncology.

Immunobiome is a biotechnology company focused on developing microbiome-based therapeutics aimed at treating challenging diseases, including cancer, autoimmune disorders, allergies, and neurological conditions. By leveraging advanced immunology, bioinformatics, and fundamental microbiome research, the company seeks to create innovative solutions that address conditions often deemed incurable. Its platform specializes in targeted treatments that can help manage intractable immune-related diseases and improve patient outcomes in various health challenges, including organ transplant rejections and inflammation-related issues.

G2GBIO specializes in biotechnology, focusing on the development and supply of sustained-release pharmaceuticals using its proprietary microsphere technology (InnoLAMP). The company aims to improve patient outcomes globally by extending drug half-life and enhancing delivery systems.

Haoxinqing is an online medical service platform that specializes in mental psychology and chronic disease management. The company offers remote diagnosis and treatment services, allowing patients to access medical care conveniently from their homes. By focusing on these areas, Haoxinqing aims to enhance patient experience and improve health outcomes, making it easier for individuals to manage their mental health and chronic conditions effectively.

Medizen Humancare, founded in 2012 and headquartered in Seoul, South Korea, is a research company specializing in genomic analysis to predict individual disease risks. The company offers services such as M-CHECK, which analyzes patients' genetic risk for specific diseases using gene chips or analysis kits, and MELTHY (DTC), a DNA analysis service. Medizen Humancare's work involves acquiring disease-specific genome contents, identifying new drug candidate genes, and developing preventive measures, with a focus on guiding disease prevention and extending healthy life spans through personalized genetic insights.

Pharos iBio Co. is a company focused on the development of innovative treatments for rare and intractable diseases. Utilizing a cutting-edge drug development platform that incorporates big data and artificial intelligence, Pharos iBio aims to address significant unmet medical needs. The company’s product pipeline includes several candidate drugs, such as PHI-101-AML for refractory or relapsed acute myeloid leukemia, PHI-101-OC for platinum-resistant or refractory ovarian cancer, and PHI-101-TNBC for metastatic triple-negative breast cancer. Additionally, Pharos iBio is advancing other candidates, including PHI-201, PHI-301, and PHI-501, as part of its commitment to improving patient outcomes in challenging therapeutic areas.

PDC*line Pharma is a French-Belgium clinical-stage biotech company developing active immunotherapies for cancer using its proprietary Plasmacytoid Dendritic Cell line, PDC*line. These therapies aim to stimulate potent and scalable antitumor immune responses.

Immunobiome is a biotechnology company focused on developing microbiome-based therapeutics aimed at treating challenging diseases, including cancer, autoimmune disorders, allergies, and neurological conditions. By leveraging advanced immunology, bioinformatics, and fundamental microbiome research, the company seeks to create innovative solutions that address conditions often deemed incurable. Its platform specializes in targeted treatments that can help manage intractable immune-related diseases and improve patient outcomes in various health challenges, including organ transplant rejections and inflammation-related issues.

Inovio Pharmaceuticals specializes in developing DNA medicines to treat, prevent, and protect against diseases caused by human papillomavirus (HPV), cancer, and infectious pathogens. Its proprietary SynCon immunotherapy platform enables robust immune responses via direct intracellular delivery using a smart device. The company's lead candidate, VGX-3100, has shown promise in clinical trials for treating precancerous cervical dysplasia.

Founded in 2016, Humanscape specializes in blockchain-based health data platforms. It collects comprehensive patient health data, including genotype, clinical, and phenotype information, to facilitate drug discovery and improve treatments for intractable and rare diseases.

OncXerna Therapeutics, Inc. is a biotechnology company focused on developing precision medicines for cancer patients by utilizing an RNA-based biomarker platform. The company aims to improve patient outcomes by prospectively identifying individuals based on the unique RNA biology of their tumor microenvironments. This innovative approach enables OncXerna to match patients with targeted oncology therapies that correspond to their specific tumor characteristics. Founded in 2018 and based in Waltham, Massachusetts, with an additional location in Shanghai, China, OncXerna was formerly known as Oncologie, Inc. and changed its name in September 2020 to reflect its commitment to advancing next-generation precision medicine for a broader range of cancer patients.

Hisense Bio offers treatment for intractable dental diseases. They provide research on original technology for tooth development and dentin regeneration. They developed physiological dentin regeneration technology and periodontal ligament regeneration technology based on basic dental research . They offer treatment of intractable dental diseases such as tooth decay, dental hypersensitivity, tooth decay, dental caries, and periodontal disease.

PT HaloDoc is a digital healthcare platform based in Jakarta, Indonesia, established in 2016. The company connects patients with a network of 19,000 licensed doctors and 1,000 certified partner pharmacies through its innovative communication platform. Users can engage with medical professionals via video calls, voice calls, and chat, allowing for real-time consultations and health advice. Additionally, HaloDoc facilitates the ordering of laboratory tests that can be conducted at home, enhancing the convenience of accessing healthcare services. The platform aims to simplify and improve the healthcare experience for patients by providing easy connections to doctors, clinics, and hospitals, as well as offering medical delivery services through its partner pharmacies.

Frequency Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to repairing or reversing damage caused by degenerative diseases through its innovative Progenitor Cell Activation approach. This method utilizes a combination of small molecules to activate progenitor cells in the body, which facilitates the creation of functional tissue without the complexities of genetic engineering. The company’s lead product candidate, FX-322, is currently undergoing phase 2a clinical trials aimed at treating the underlying causes of sensorineural hearing loss. In addition to FX-322, Frequency Therapeutics is exploring treatments for various degenerative conditions, including multiple sclerosis and diseases affecting muscle, the gastrointestinal tract, skin, and bone. Established in 2014 and based in Woburn, Massachusetts, Frequency Therapeutics has established a collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322.

Founded in 2014, I.M.Lab specializes in manufacturing innovative cardiopulmonary resuscitation (CPR) training kits. Its flagship product, cprCUBE, is a sensor-based CPR training aid that assists users in learning chest compressions effectively. The company also offers HeartiSense kit for real-time data tracking and HeartiSense LMS for managing training data. I.M.Lab's products cater primarily to medical test and training institutions.

Univercells is a company specializing in high-density, low-cost biomanufacturing solutions aimed at enhancing the production of biologics, including antibodies, proteins, and vaccines. The company leverages innovative engineering and proprietary technologies, such as single-use systems and continuous process intensification, to significantly reduce capital investments by over 75% and the cost of goods by up to 90%. Univercells offers a range of services, including scale-X hydro, scale-X carbo, and NevoLine, which support both research and development and commercial-scale production of biologics. Additionally, the company provides integrated services like equipment confirmation, capacity and facility design, and bioprocess excellence, facilitating the scalability of cell and gene therapy manufacturers from clinical trials to commercial manufacturing. Through its commitment to making biologics more accessible and affordable, Univercells addresses critical global health challenges.

Genome & Company, headquartered in Seongnam, South Korea, specializes in researching microbes and probiotics to develop dietary supplements, cosmeceuticals, and novel drugs targeting conditions such as obesity, diabetes, acne, atopic dermatitis, and cancer-related therapies.

G2GBIO specializes in biotechnology, focusing on the development and supply of sustained-release pharmaceuticals using its proprietary microsphere technology (InnoLAMP). The company aims to improve patient outcomes globally by extending drug half-life and enhancing delivery systems.

Infit & Company Inc. is a manufacturer of medical diagnostic devices and wellness devices that targeting global healthcare industry.

Olive Healthcare is a company specializing in digital healthcare and medical diagnostic devices. It focuses on abdominal fat scanning and breast cancer diagnosis by utilizing non-radiative and non-invasive near infrared (NIR) technology. The company employs artificial intelligence algorithms and big data processing to deliver customized medical services. Olive Healthcare's devices not only measure abdominal fat but also offer personalized exercise and diet guidance based on individual health metrics. By providing these tailored services, the company aims to assist users in reducing belly fat and mitigating the risk of metabolic diseases.

Hisense Bio offers treatment for intractable dental diseases. They provide research on original technology for tooth development and dentin regeneration. They developed physiological dentin regeneration technology and periodontal ligament regeneration technology based on basic dental research . They offer treatment of intractable dental diseases such as tooth decay, dental hypersensitivity, tooth decay, dental caries, and periodontal disease.

Perception Point is a Tel Aviv-based cybersecurity company offering a cloud-based, AI-powered platform that prevents cyber threats across enterprise collaboration channels. The platform supports real-time threat detection and response for email, web, and cloud security, protecting organizations from advanced threats and phishing. It serves industries including finance, healthcare, and education, helping customers safeguard their data and networks against attacks across communication and collaboration tools.

KBP is a leading biotechnology company focused on developing innovative therapies for unmet medical needs in areas such as cardiovascular, respiratory, inflammatory, and autoimmune diseases. It leverages a proprietary compound library and expertise in organ-specific disease models to deliver advanced therapeutic innovations.

Genome & Company, headquartered in Seongnam, South Korea, specializes in researching microbes and probiotics to develop dietary supplements, cosmeceuticals, and novel drugs targeting conditions such as obesity, diabetes, acne, atopic dermatitis, and cancer-related therapies.

Otus is a healthcare institute that specializes in advanced eyecare system.

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of novel drugs targeting rare and ultra-rare genetic diseases caused by nonsense mutations. Founded in 2013, the company is focused on discovering and commercializing ribonucleic acid modulating drug candidates. Its lead investigational product, ELX-02, is currently undergoing Phase 2 clinical trials aimed at treating cystic fibrosis and nephropathic cystinosis in patients with specific nonsense mutations. Eloxx utilizes its advanced technology platform to create oral small molecules that can induce ribosomal readthrough, thereby enabling the production of full-length functional proteins. The company is building a robust pipeline of therapeutic candidates designed to address various genetic disorders, including Duchenne Muscular Dystrophy and Tay-Sachs syndrome, by overcoming the limitations posed by premature stop codons.

Frequency Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to repairing or reversing damage caused by degenerative diseases through its innovative Progenitor Cell Activation approach. This method utilizes a combination of small molecules to activate progenitor cells in the body, which facilitates the creation of functional tissue without the complexities of genetic engineering. The company’s lead product candidate, FX-322, is currently undergoing phase 2a clinical trials aimed at treating the underlying causes of sensorineural hearing loss. In addition to FX-322, Frequency Therapeutics is exploring treatments for various degenerative conditions, including multiple sclerosis and diseases affecting muscle, the gastrointestinal tract, skin, and bone. Established in 2014 and based in Woburn, Massachusetts, Frequency Therapeutics has established a collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322.

ABL Bio Inc. is a biotechnology research company based in Seongnam, South Korea, dedicated to the development of therapeutic drugs aimed at treating immuno-oncology and neurodegenerative diseases. The company's pipeline includes several innovative products, such as ABL001, a bispecific antibody for cancer immunotherapy, and ABL301, designed to penetrate the blood-brain barrier. ABL Bio also focuses on antibody-drug conjugates and dual immune cell targeting bispecific antibodies, reflecting its commitment to advancing novel therapies in the biotech sector. Through its research and development efforts, ABL Bio aims to improve patients' lives by delivering effective and innovative treatment options.

Celleron Therapeutics Ltd is an oncology company specializing in the clinical development of innovative cancer therapies. Founded in 2004 and based in Oxford, United Kingdom, the company focuses on personalized medicine by leveraging epigenetic techniques to match patients with treatments that are likely to be effective for them. Its clinical product pipeline includes CXD101, an epigenetic immune-regulator designed to enhance the immune system's recognition of tumor cells, and CXD201, a compound derived from the homocamptothecin family known for its unique chemical composition and improved pharmacological properties. Celleron aims to advance a new class of mechanism-based cancer drugs that increase treatment success rates, minimize side effects, and promote more cost-effective healthcare solutions.

Elastagen is a clinical-stage medical company focused on developing products based on human protein tropoelastin, a vital component for tissues that require elasticity, such as skin and blood vessels. The company has created a synthetic version of elastin that mirrors the natural protein found in the human body, allowing for innovative applications in skin rejuvenation, scar remodeling, and tissue repair. Elastagen's offerings include injectable synthetic human elastin and chemically cross-linked tropoelastin for aesthetic purposes, aimed at helping patients maintain skin elasticity and suppleness. Founded through the acquisition of intellectual property from research conducted by Prof Weiss at the University of Sydney, Elastagen has attracted significant investment from both Australian and international life science venture capital groups. Its operations have grown from Australia to include production facilities in Europe and clinical activities in the UK.

KAHR medical is a biopharmaceutical company developing fusion protein drugs for cancer and autoimmune disease treatment. Founded in 2005, it specializes in immuno-oncology, focusing on T-cell mediated tumor destruction and targeting CD47 tumors.

BioPharmX Corporation is a specialty pharmaceutical company focused on developing innovative treatments for dermatologic conditions through its proprietary HyantX topical delivery system. The company’s clinical-stage product candidates include BPX01, a topical antibiotic gel that has completed Phase IIb trials for treating inflammatory lesions of acne, and BPX04, which is in Phase IIb studies for papulopustular rosacea. BioPharmX aims to address unmet medical needs in large and underserved markets, particularly within dermatology, women's health, and Ear, Nose, and Throat (ENT) therapy. The company leverages its patented drug delivery technologies to create novel prescription products and is supported by a team with extensive experience in pharmaceutical development, regulatory compliance, and intellectual property. Based in Campbell, California, BioPharmX serves a range of clients, including pharmaceutical companies, healthcare providers, and dermatologists.